Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745081 | 0.90 | TGFBR1 (0.41) | TGFBR1TGFBR2ROCK2F10 | |
| SCHEMBL3719028 | 0.87 | TGFBR1 (0.34) | TGFBR1GAAROCK2F10 | |
| SCHEMBL13013500 | 0.82 | TGFBR1 (0.36) | TGFBR1TGFBR2 | |
| SCHEMBL13013521 | 0.81 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL13013506 | 0.80 | TGFBR1 (0.37) | TGFBR1TGFBR2F10 | |
| SCHEMBL13062608 | 0.80 | TGFBR1 (0.35) | TGFBR1TGFBR2ROCK2 | |
| SCHEMBL13013480 | 0.76 | PIM1 (0.41) | TGFBR1TGFBR2ROCK2 | |
| SCHEMBL13013512 | 0.73 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL13013499 | 0.73 | PIM1 (0.38) | TGFBR1ROCK2 | |
| SCHEMBL3721115 | 0.71 | GAA (0.38) | GAAROCK2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323994-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP4K2, MAP3K15 | TGFBR1 2134/4885GAA 2669/4885TGFBR2 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.